Compare VC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VC | MESO |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United States | Australia |
| Employees | 10000 | 81 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.2B |
| IPO Year | 2000 | N/A |
| Metric | VC | MESO |
|---|---|---|
| Price | $92.80 | $16.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $120.75 | N/A |
| AVG Volume (30 Days) | ★ 433.7K | 269.4K |
| Earning Date | 04-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.28 | N/A |
| Revenue | ★ $3,768,000,000.00 | N/A |
| Revenue This Year | $2.26 | $644.56 |
| Revenue Next Year | $5.19 | $38.63 |
| P/E Ratio | $12.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $69.88 | $9.88 |
| 52 Week High | $128.32 | $21.50 |
| Indicator | VC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 57.73 |
| Support Level | $89.31 | $15.62 |
| Resistance Level | $106.35 | $16.65 |
| Average True Range (ATR) | 3.06 | 0.53 |
| MACD | 0.48 | 0.20 |
| Stochastic Oscillator | 58.15 | 87.34 |
Visteon Corp is an automotive supplier. It manufactures electronics products for original equipment vehicle manufacturers including Ford, Nissan, Renault, Mazda, BMW, General Motors, and Honda, etc. The company offers information displays, instrument clusters, head-up displays, infotainment systems, telematics solutions, and Smartcore. The Company's reportable segment is Electronics. The Electronics segment provides vehicle cockpit electronics products to customers, including digital instrument clusters, domain controllers with integrated driver assistance systems, displays, Android-based infotainment systems, and battery management systems. Geographically, it operates in North America, Europe, China, Asia-Pacific, and South America and Others.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.